PMID- 32631456
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20210712
IS  - 2047-2994 (Electronic)
IS  - 2047-2994 (Linking)
VI  - 9
IP  - 1
DP  - 2020 Jul 6
TI  - Containing Carbapenemase-producing Klebsiella pneumoniae in an endemic setting.
PG  - 102
LID - 10.1186/s13756-020-00766-x [doi]
LID - 102
AB  - BACKGROUND: Carbapenemase-producing K. pneumoniae (CP-Kp) has been established as 
      important nosocomial pathogen in most tertiary care hospitals in Greece. The aim 
      of the present study was to examine the impact of an enhanced infection control 
      program on the containment of CP-Kp in a haematology unit where the incidence of 
      CP-Kp infections was high. METHODS: The study was conducted from June 2011 to 
      December 2014 in a haematology unit of a tertiary-care 500-bed hospital located 
      in Athens, Greece. A bundled intervention (active surveillance cultures, 
      separation of carriers from non-carriers, assignment of dedicated nursing staff, 
      contact precautions, environmental cleaning, and promotion of hand hygiene) was 
      tested whether would reduce colonization and infection caused by CP-Kp. RESULTS: 
      A total of 2507 rectal swabs were obtained; 1199 upon admission from June 2011 to 
      June 2013 and 1307 during hospitalization from June 2011 to December 2012. During 
      intervention the admission prevalence of CP-Kp colonization (p < 0.001 for linear 
      trend), the hospitalization prevalence (p = 0.001 for linear trend) and the 
      incidence rate of CP-Kp colonization (p = 0.072 for linear trend) were declining. 
      Application of segmented linear regression revealed that both the change in the 
      level of CP-Kp BSI incidence rates (p = 0.001) as well as the difference between 
      pre- and post-intervention slopes were statistically significant (p < 0.001). 
      CONCLUSIONS: A bundled intervention including active surveillance cultures on 
      admission can attain maximum containment of CP-Kp colonization and infection in 
      endemic acute healthcare settings.
FAU - Spyridopoulou, Kalliopi
AU  - Spyridopoulou K
AD  - First Department of Medicine, Medical School, "Laiko" General Hospital, National 
      and Kapodistrian University of Athens, 75, 11527, Athens, Greece.
FAU - Psichogiou, Mina
AU  - Psichogiou M
AD  - First Department of Medicine, Medical School, "Laiko" General Hospital, National 
      and Kapodistrian University of Athens, 75, 11527, Athens, Greece.
FAU - Sypsa, Vana
AU  - Sypsa V
AD  - Department of Hygiene, Epidemiology and Medical Statistics, Medical School, 
      National and Kapodistrian University of Athens, Athens, Greece.
FAU - Miriagou, Vivi
AU  - Miriagou V
AD  - Laboratory of Bacteriology, Hellenic Pasteur Institute, Athens, Greece.
FAU - Karapanou, Amalia
AU  - Karapanou A
AD  - First Department of Medicine, Medical School, "Laiko" General Hospital, National 
      and Kapodistrian University of Athens, 75, 11527, Athens, Greece.
FAU - Hadjihannas, Linos
AU  - Hadjihannas L
AD  - First Department of Medicine, Medical School, "Laiko" General Hospital, National 
      and Kapodistrian University of Athens, 75, 11527, Athens, Greece.
FAU - Tzouvelekis, Leonidas
AU  - Tzouvelekis L
AD  - Department of Microbiology, School of Medicine, National and Kapodistrian 
      University of Athens, Athens, Greece.
FAU - Daikos, George L
AU  - Daikos GL
AD  - First Department of Medicine, Medical School, "Laiko" General Hospital, National 
      and Kapodistrian University of Athens, 75, 11527, Athens, Greece. 
      gdaikos@med.uoa.gr.
LA  - eng
PT  - Journal Article
DEP - 20200706
PL  - England
TA  - Antimicrob Resist Infect Control
JT  - Antimicrobial resistance and infection control
JID - 101585411
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Bacterial Proteins)
RN  - 0 (Carbapenems)
RN  - EC 3.5.2.6 (beta-Lactamases)
RN  - EC 3.5.2.6 (carbapenemase)
SB  - IM
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Bacterial Proteins/*genetics
MH  - Carbapenems/pharmacology
MH  - Cross Infection/epidemiology/*prevention & control
MH  - Endemic Diseases/prevention & control
MH  - Greece/epidemiology
MH  - Humans
MH  - Infection Control/*methods
MH  - Klebsiella Infections/epidemiology/*prevention & control
MH  - Klebsiella pneumoniae/*drug effects/enzymology
MH  - Prevalence
MH  - Tertiary Care Centers
MH  - beta-Lactamases/*genetics
PMC - PMC7339575
OTO - NOTNLM
OT  - Active surveillance
OT  - Carbapenemases
OT  - Hospital-acquired infection
OT  - Infection control
OT  - Klebsiella pneumoniae
COIS- All authors report no competing interests relevant to this article.
EDAT- 2020/07/08 06:00
MHDA- 2021/07/13 06:00
PMCR- 2020/07/06
CRDT- 2020/07/08 06:00
PHST- 2020/04/10 00:00 [received]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/07/08 06:00 [entrez]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
PHST- 2020/07/06 00:00 [pmc-release]
AID - 10.1186/s13756-020-00766-x [pii]
AID - 766 [pii]
AID - 10.1186/s13756-020-00766-x [doi]
PST - epublish
SO  - Antimicrob Resist Infect Control. 2020 Jul 6;9(1):102. doi: 
      10.1186/s13756-020-00766-x.